MacDonald, Karen V.Heidenreich, SebastianKrucien, NicolasBoycott, Kym M.Bernier, Francois P.Ryan, MandyMarshall, Deborah A.2025-11-272025-11-12MacDonald, K V, Heidenreich, S, Krucien, N, Boycott, K M, Bernier, F P, Ryan, M & Marshall, D A 2025, 'Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation', European Journal of Health Economics. https://doi.org/10.1007/s10198-025-01870-81618-7601RIS: urn:B9DBB36193C30CA3AAD60FB3246F53E0RIS: MacDonald2025https://hdl.handle.net/2164/26477925087engSDG 3 - Good Health and Well-beingNext generation sequencingRare diseasesPatient preferencesUser-based valuationD61 (Allocative Efficiency, Cost-Benefit Analysis)I18 (Government Policy, Regulation, Public Health)I12 (Health Behavior)I11 (Analysis of Health Care Markets)R Medicine (General)Economics, Econometrics and Finance (miscellaneous)Health PolicyR1Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuationJournal article10.1007/s10198-025-01870-8https://www.scopus.com/pages/publications/105021534401